Pipeline Agents in Clinical Development

TAR-200 is a first-in-class intravesical drug-releasing system designed for the sustained delivery of gemcitabine directly into the bladder. Unlike conventional intravesical instillation which requires periodic catheterisation, TAR-200 is a pretzel-shaped silicone device that is placed in the bladder and continuously releases gemcitabine over approximately 3 weeks before being removed and replaced.

This sustained-release approach addresses a key limitation of conventional intravesical therapy: the short dwell time (typically 1–2 hours) that limits drug exposure to tumour cells. TAR-200 provides continuous gemcitabine exposure for 21 days per cycle, potentially maximising anti-tumour efficacy while maintaining a favourable local safety profile.

Cretostimogene grenadenorepvec (CG0070) is a cancer-selective oncolytic adenovirus engineered to preferentially replicate within tumour cells harbouring defective retinoblastoma (Rb) pathways — a hallmark of high-grade urothelial carcinoma. Upon selective replication and lysis of tumour cells, CG0070 releases granulocyte-macrophage colony-stimulating factor (GM-CSF) and tumour neoantigens into the microenvironment, triggering robust anti-tumour immune responses.

The mechanism involves: (1) selective viral replication in Rb-defective tumour cells, (2) oncolysis and release of GM-CSF, (3) dendritic cell activation and neoantigen presentation, and (4) cytotoxic T-lymphocyte mediated tumour killing. This dual mechanism of direct oncolysis plus immune activation provides a potent anti-tumour effect.